The National Academies Press

Currently Skimming:

INDEX
Pages 217-224

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.

From page 217... ... , 176, 179 American Health Security Act, 197 American Medical Association, 19, 175 Antitrust law, 5, 62 Appropriateness studies, 137 Auranofin, 159 Australia, 50, 55 Autologous bone marrow transplant. See Bone marrow transplantation for breast cancer AZT,18,30, 103 217 Battelle Memorial Institute, 176 Benefit coverage Blue Cross/Blue Shield technology assessment, 97-98 for bone marrow transplantation in breast cancer, 112-116. Read the entire page →
From page 218... ... . as dec~s~on-mak~ng criterion In Medicare, 89, 92 as drug evaluation criterion, SS economic modeling for evaluation of, 161, 162 in pharmaceutical research, 160 in research and development process, 89 standards for measuring, 190 as technology assessment criterion, 8, 104, 142-143 of vaccines, 23 n.21 Cost of care for catastrophic care, 14 cost of education vs., 40-41 cost of monitoring in, 34-35 inHDC-ABMT, 110 health care expenditures, 11, 14 in HMOs, 27 medical technology in, 19, 22, 25-26, 39 in myocardial infarction, 22 n.20 physician payment in, 71 prospective payment system and, 26-27 public understanding of, 146 retrospective payment system and, 25 26 See also Cost containment; Cost effectiveness Credentialing issues, 80 Cyclosporine, 30 Data registries, 133 Decision analysis, 138-139 Diabetic retinopathy, 78 Diagnosis-related groups (DRGs) Read the entire page →
From page 219... ... See Bone marrow transplantation for breast cancer Health Care Cost Reduction Act, 194 Health Care Financing Administration, 5, 219 50, 55, 80, 156, 159, 164-165, 176, 179, 198 Medicare coverage decisionmaking in, 87,91-94 Uniform Clinical Data Set, 135 Health care market, 17-19 Health care reform comparative value decisions in, 145 goals of, 97 historical developments, 14-15, 16 legislative background, 193-195 medical technology and, 3 - , 196-199 private sector-public sector roles in, 195-196, 197-199 technology assessment in, 49, 185-186, 191 Health Equity and Access Reform Today Act, 195 Health Insurance Association of America, 53 Health maintenance organizations (HMOs) cost-containment in, 15, 27 experimental therapies in, 102 financial incentives to reduce quality in, 35 n.40 growth of, 16 technology adoption in, 39 n.47 technology assessment in, 51, 53, 54, 56 vs. Read the entire page →
From page 220... ... See also Reimbursement systems determinants of demand in, 20-21 evaluation of HDC-ABMT for breast cancer, 112-113 evaluation of special cases in, 106-107 evolution of, 10, 14-15, 16 expenditures, 14, 15 health care conceptualization in, 17-19 indemnity insurance, 25 n.24 judicial view of, 118 legal history of experimental exclusions in, 117-123 Medicare coverage decisionmaking and, 91-92 pharmaceutical coverage, 80 physician relations with, 119 preventive interventions and, 30-31 as public interest, 12-13, 118 social choice modeling of, 16-17 taxation in, 188 in technology assessment, 176, 182-187 technology development and, 11, 15-16, 19-33, 39-40 in technology research and development, 11, 15-16 International comparisons cost-effectiveness as decision-making criterion, 50, 55 R & D environment, 13 INDEX Jackson Hole Group, 185-186 Japan, 13 Joint Commission on Accreditation of Health Care Organizations, 35, 69 Kaiser Permanente organizational structure, 101-102 technology assessment activities, 98, 102-108 Laparoscopy, in cholecystectomy, 68, 77 Legal issues bone marrow transplantation in breast cancer, 110 coverage for experimental therapies, 117-123 expert witnesses, 119-120 hospital responsibilities, 62 in technology adoption, 62-63 in technology assessment, 106 Length of stay, 37, 67 Life expectancy, 20 Lithotripsy, 103 Liver transplants, 14, 21, 30, 92-93, 143 Magnetic resonance imaging, 80, 91 Managed care, 3 Managed competition, 196, 197 Managed Competition Act, 195 Medicaid, 12, 14, 145 cost-effectiveness as coverage criterion in, 55 Medical Assessment Directory, 175 Medical device manufacturers, technology assessment and, 155-159, 168-169, 175, 180-181 Medical technology in cost of care, 19, 22-23, 25-26, 39 coverage decisionmaking and, 4-5 definition, 173 diffusion of, 128-129 health care reform and, 196-199 historical development, 13-15 inappropriate use, 129 in insurance definition of health care, 17-19 Read the entire page →
From page 221... ... INDEX In model of hospital management, 6365 stage model, 22-23 See also Research and development; Technology adoption; and Technology assessment Medicare, 12, 14, 50, 164, 176, 188 capital budgets and, 62 cost-effectiveness as coverage criterion in, 89, 92 coverage decisionmaking in, 87, 88-90, 91-94 criticisms of, 88-90 diagnosis-related group system in, 9, 15 evolution of, 87-88, 94 outcomes data, 134 prospective payment system in, 27 reimbursement system, 90-91 Meta-analysis, 135-137 Methodology appropriateness, 137, 140-141 cost-effectiveness calculations, 142-143 decision analysis, 138-139 economic modeling, 161, 162 in manufacturer-sponsored technology assessment, 181 meta-analysis, 135-137 outcomes measurement, 130-135, 154 pharmaceutical industry outcomes research, 161-162 surrogate outcomes in technology assessment, 75-76 technology assessment standards, 189190 Minimum benefits package, 6 Myocardial infarction cost per case, 22 n.20 surrogate outcomes in treatment evaluation, 76 National Cancer Institute, 5, 110, 112 National Center for Health Statistics, 198 National Institutes of Health, 24, 175, 176, 177, 198 Nonprofit organizations, 37-39 221 Office of Health Technology Assessment, 53, 148, 157 Office of Technology Assessment, 53 Oregon, 55, 145-146, 147 Outcomes research, 6 appropriateness methodology and, 140141 in biotechnology pharmaceutical companies, 16~165, 166 clinical application, 167-168 consultants for, 162-163 cost of, 168 data sources, 131-135, 154 definition, 153-154 dissemination of, 76-78 economics of, 144 evaluation in, 135-137 evolution of, l5ilS5 future of, 166-170 HDC-ABMT, 111-112 by medical device manufacturers, 156, 157-158, 165-166, 168-169 meta-analysis in, 135-137 Patient Outcomes Research Teams for, 137-138, 167 by pharmaceutical companies, 159-161, 166, 169 surrogate outcomes in, 75-76 in technology assessment, 53, 56, 6668, 72, 75-76, 78, 113, 115, 153, 154-155 type of outcomes in, 130-131 See also Quality of care; Technology assessment Parenteral/enteral feeding, 89 Patient Outcomes Research Teams, 137138, 167 Patient Shared Decision-Making, 141-142 Peer review, 80, 93-94 Pharmacotherapy biotechnology research, 164-165 as complement to surgery, 29-30 drug formularies, 50 n.l, 155 experimental, insurance coverage for, 18 innovation in, 10 Medicare coverage for, 88-89 Read the entire page →
From page 222... ... Provisional coverage, 5-6 Public education system, 40~1 Public knowledge, 77-78 Quality-adjusted life years, 142 Quality of care INDEX conceptual evolution, 127-128 cost of monitonng, 3~35 ~ in prospective payment system, 33-37 See also Outcomes research; Technology assessment Randomized clinical seals expenditures, 177 in meta-analysis, 135-137 methodology, 132 role of, 154 as stage III technology assessments, 172-173 n.2, 173 Regulatory environment in Blue Cross/Blue Shield technology assessment, 97-98 development of health care reform in, 193-196 experimental exclusions in insurance coverage and, 121 pharmaceutical manufacturing in, 159 in technology assessment, 55, 62-63 Reilly v. Blue Cross and Blue Shield, 121122 Reimbursement systems cost-effectiveness as criterion in, 5 cost of care and, 25-27 development of, 1~15 discharge decisions and, 37-39 experimental therapies and, 5-6, 18 in HMOs, 15 in Medicare, 90-91 in Medicare DRG, 15 new drug development and, 29, 30 social choice modeling, 16-17 in technology adoption, 33-36 technology adoption and, 80, 91 technology assessment and, 62, 72 technology development and, 9, 25, 28 Research and development in biotechnology companies, 16~165 collaborative efforts, 5, 56, 57, 185-186 cost-effectiveness evaluation in, 8-10 coverage for experimental therapies, 56 diagnosis-related group system and, 910 Read the entire page →
From page 223... ... . dec~s~on-mak~ng criteria, 4 diagnosis-related group system and, 910 effects on technology development, 24 health care reform and, 3-4 in HMOs, 39 n.47 in hospitals, 61-69 individual physician characteristics in, 74-75, 76 insurance-related incentives in, 28 marketing considerations, 79 223 physician behavior in, 73, 80-81 process, 128-129 public participation in, 146-147 reimbursement systems and, 25, 33-36, 72, 80 reimbursement systems in, 91 research needs, 81 societal context of, 78-79 Technology assessment alternative funding mechanisms, 184188 appropriateness methodology for, 138, 140-141 in biotechnology pharmaceutical companies, 164-165 in Blue Cross and Blue Shield Association, 96-98 categories of technology for, 103-104 collaboration in, 56, 57, 113, 114-115, 185-186 committees for, 51, 54, 63 consumers and, 176, 182 cost-benefit analysis, 141-143, 144-145 cost-effectiveness as criterion in, 8 cost of research in, 54, 57 current practice in, 51-53, 63 decision analysis in, 139-139 decision-making criteria, 4 definition, 49-50, 152, 154, 173-174 drug formulary, 50 n.1, 54 early-stage sponsorship, 189 economic considerations in, 55-56, 6263, 104-105 education/training for, 57 effectiveness in, 130 efficacy as measure in, 130, 153, 173 evolution of, 154-155 expenditures, 176-177 experimental trials, 79 government support for, 127, 175, 176, 183, 187-189, 198-199 health care reform and, 198 in hospitals, 62-63 information resources, 4, 53, 54-55, 56, 57-58, 72, 75-78, 79, 198-199 in Kaiser Permanente, 102-108 marketing considerations in, 180-181 Read the entire page →
From page 224... ... 224 INDEX medical device manufacturers and, 6, 155-159, 168-169, 175, 180-181 care in Medicare coverage decisions, 90, 92 models of management behavior in, 63 65 national body/procedures for, 113-115, 147-148, 185-186, 198 negative findings in, 181 obsolescence as evaluation criterion, 81 obstacles to, 56-57, 81, 143-147, 190 optimal process, 148-149 outcomes research in, 130-131, 153 patient perspective in, 141-142 by pharmaceutical companies, 159-164, 169, 175, 180-181 quality-adjusted life years, 142 quality of, 53-55 regulatory considerations, 55 responsibility for, 6 role of, 49, 50, 53, 128, 190-191 selection of technologies for, 177-179 short-term vs. long-term outcomes in, 66-68 societal perspectives in, 65-69, 105- system, 27 106, 107-108 sponsors of 174-176, 179-184, 181, 186-188, 190-191 stages of, 173-174 standards, 189-190 timing of, 66 trends, 56-58, 166 See also Outcomes research; Quality of Third-party payers in Medicare coverage decisionmaking, 91-92 technology assessment by, 51, 53, 54, 149, 156 Tissue plasminogen activator, 30 Transplant procedures, 14, 19, 21, 25-26, 30 in Medicare coverage, 92-93 Travelers' Insurance, 91-92 Treatment decisions cost-benefit analysis in, 145-146 coverage decisionmaking and, 4-5 influences in, 4 patient perspective in, 141-142 Uniform Clinical Data Set, 135 United Kingdom, 13 dialysis coverage in, 20 Unnecessary operations, 12 n.6 Utilization, in prospective payment Vaccines, 20-21, 22-23 Veterans Affairs, Department of, 176, 177 Victim v. Read the entire page →

From page 217...

... , 176, 179 American Health Security Act, 197 American Medical Association, 19, 175 Antitrust law, 5, 62 Appropriateness studies, 137 Auranofin, 159 Australia, 50, 55 Autologous bone marrow transplant. See Bone marrow transplantation for breast cancer AZT,18,30, 103 217 Battelle Memorial Institute, 176 Benefit coverage Blue Cross/Blue Shield technology assessment, 97-98 for bone marrow transplantation in breast cancer, 112-116.

Read the entire page →

From page 218...

... . as dec~s~on-mak~ng criterion In Medicare, 89, 92 as drug evaluation criterion, SS economic modeling for evaluation of, 161, 162 in pharmaceutical research, 160 in research and development process, 89 standards for measuring, 190 as technology assessment criterion, 8, 104, 142-143 of vaccines, 23 n.21 Cost of care for catastrophic care, 14 cost of education vs., 40-41 cost of monitoring in, 34-35 inHDC-ABMT, 110 health care expenditures, 11, 14 in HMOs, 27 medical technology in, 19, 22, 25-26, 39 in myocardial infarction, 22 n.20 physician payment in, 71 prospective payment system and, 26-27 public understanding of, 146 retrospective payment system and, 25 26 See also Cost containment; Cost effectiveness Credentialing issues, 80 Cyclosporine, 30 Data registries, 133 Decision analysis, 138-139 Diabetic retinopathy, 78 Diagnosis-related groups (DRGs)

Read the entire page →

From page 219...

... See Bone marrow transplantation for breast cancer Health Care Cost Reduction Act, 194 Health Care Financing Administration, 5, 219 50, 55, 80, 156, 159, 164-165, 176, 179, 198 Medicare coverage decisionmaking in, 87,91-94 Uniform Clinical Data Set, 135 Health care market, 17-19 Health care reform comparative value decisions in, 145 goals of, 97 historical developments, 14-15, 16 legislative background, 193-195 medical technology and, 3 - , 196-199 private sector-public sector roles in, 195-196, 197-199 technology assessment in, 49, 185-186, 191 Health Equity and Access Reform Today Act, 195 Health Insurance Association of America, 53 Health maintenance organizations (HMOs) cost-containment in, 15, 27 experimental therapies in, 102 financial incentives to reduce quality in, 35 n.40 growth of, 16 technology adoption in, 39 n.47 technology assessment in, 51, 53, 54, 56 vs.

Read the entire page →

From page 220...

... See also Reimbursement systems determinants of demand in, 20-21 evaluation of HDC-ABMT for breast cancer, 112-113 evaluation of special cases in, 106-107 evolution of, 10, 14-15, 16 expenditures, 14, 15 health care conceptualization in, 17-19 indemnity insurance, 25 n.24 judicial view of, 118 legal history of experimental exclusions in, 117-123 Medicare coverage decisionmaking and, 91-92 pharmaceutical coverage, 80 physician relations with, 119 preventive interventions and, 30-31 as public interest, 12-13, 118 social choice modeling of, 16-17 taxation in, 188 in technology assessment, 176, 182-187 technology development and, 11, 15-16, 19-33, 39-40 in technology research and development, 11, 15-16 International comparisons cost-effectiveness as decision-making criterion, 50, 55 R & D environment, 13 INDEX Jackson Hole Group, 185-186 Japan, 13 Joint Commission on Accreditation of Health Care Organizations, 35, 69 Kaiser Permanente organizational structure, 101-102 technology assessment activities, 98, 102-108 Laparoscopy, in cholecystectomy, 68, 77 Legal issues bone marrow transplantation in breast cancer, 110 coverage for experimental therapies, 117-123 expert witnesses, 119-120 hospital responsibilities, 62 in technology adoption, 62-63 in technology assessment, 106 Length of stay, 37, 67 Life expectancy, 20 Lithotripsy, 103 Liver transplants, 14, 21, 30, 92-93, 143 Magnetic resonance imaging, 80, 91 Managed care, 3 Managed competition, 196, 197 Managed Competition Act, 195 Medicaid, 12, 14, 145 cost-effectiveness as coverage criterion in, 55 Medical Assessment Directory, 175 Medical device manufacturers, technology assessment and, 155-159, 168-169, 175, 180-181 Medical technology in cost of care, 19, 22-23, 25-26, 39 coverage decisionmaking and, 4-5 definition, 173 diffusion of, 128-129 health care reform and, 196-199 historical development, 13-15 inappropriate use, 129 in insurance definition of health care, 17-19

Read the entire page →

From page 221...

... INDEX In model of hospital management, 6365 stage model, 22-23 See also Research and development; Technology adoption; and Technology assessment Medicare, 12, 14, 50, 164, 176, 188 capital budgets and, 62 cost-effectiveness as coverage criterion in, 89, 92 coverage decisionmaking in, 87, 88-90, 91-94 criticisms of, 88-90 diagnosis-related group system in, 9, 15 evolution of, 87-88, 94 outcomes data, 134 prospective payment system in, 27 reimbursement system, 90-91 Meta-analysis, 135-137 Methodology appropriateness, 137, 140-141 cost-effectiveness calculations, 142-143 decision analysis, 138-139 economic modeling, 161, 162 in manufacturer-sponsored technology assessment, 181 meta-analysis, 135-137 outcomes measurement, 130-135, 154 pharmaceutical industry outcomes research, 161-162 surrogate outcomes in technology assessment, 75-76 technology assessment standards, 189190 Minimum benefits package, 6 Myocardial infarction cost per case, 22 n.20 surrogate outcomes in treatment evaluation, 76 National Cancer Institute, 5, 110, 112 National Center for Health Statistics, 198 National Institutes of Health, 24, 175, 176, 177, 198 Nonprofit organizations, 37-39 221 Office of Health Technology Assessment, 53, 148, 157 Office of Technology Assessment, 53 Oregon, 55, 145-146, 147 Outcomes research, 6 appropriateness methodology and, 140141 in biotechnology pharmaceutical companies, 16~165, 166 clinical application, 167-168 consultants for, 162-163 cost of, 168 data sources, 131-135, 154 definition, 153-154 dissemination of, 76-78 economics of, 144 evaluation in, 135-137 evolution of, l5ilS5 future of, 166-170 HDC-ABMT, 111-112 by medical device manufacturers, 156, 157-158, 165-166, 168-169 meta-analysis in, 135-137 Patient Outcomes Research Teams for, 137-138, 167 by pharmaceutical companies, 159-161, 166, 169 surrogate outcomes in, 75-76 in technology assessment, 53, 56, 6668, 72, 75-76, 78, 113, 115, 153, 154-155 type of outcomes in, 130-131 See also Quality of care; Technology assessment Parenteral/enteral feeding, 89 Patient Outcomes Research Teams, 137138, 167 Patient Shared Decision-Making, 141-142 Peer review, 80, 93-94 Pharmacotherapy biotechnology research, 164-165 as complement to surgery, 29-30 drug formularies, 50 n.l, 155 experimental, insurance coverage for, 18 innovation in, 10 Medicare coverage for, 88-89

Read the entire page →

From page 222...

... Provisional coverage, 5-6 Public education system, 40~1 Public knowledge, 77-78 Quality-adjusted life years, 142 Quality of care INDEX conceptual evolution, 127-128 cost of monitonng, 3~35 ~ in prospective payment system, 33-37 See also Outcomes research; Technology assessment Randomized clinical seals expenditures, 177 in meta-analysis, 135-137 methodology, 132 role of, 154 as stage III technology assessments, 172-173 n.2, 173 Regulatory environment in Blue Cross/Blue Shield technology assessment, 97-98 development of health care reform in, 193-196 experimental exclusions in insurance coverage and, 121 pharmaceutical manufacturing in, 159 in technology assessment, 55, 62-63 Reilly v. Blue Cross and Blue Shield, 121122 Reimbursement systems cost-effectiveness as criterion in, 5 cost of care and, 25-27 development of, 1~15 discharge decisions and, 37-39 experimental therapies and, 5-6, 18 in HMOs, 15 in Medicare, 90-91 in Medicare DRG, 15 new drug development and, 29, 30 social choice modeling, 16-17 in technology adoption, 33-36 technology adoption and, 80, 91 technology assessment and, 62, 72 technology development and, 9, 25, 28 Research and development in biotechnology companies, 16~165 collaborative efforts, 5, 56, 57, 185-186 cost-effectiveness evaluation in, 8-10 coverage for experimental therapies, 56 diagnosis-related group system and, 910

Read the entire page →

From page 223...

... . dec~s~on-mak~ng criteria, 4 diagnosis-related group system and, 910 effects on technology development, 24 health care reform and, 3-4 in HMOs, 39 n.47 in hospitals, 61-69 individual physician characteristics in, 74-75, 76 insurance-related incentives in, 28 marketing considerations, 79 223 physician behavior in, 73, 80-81 process, 128-129 public participation in, 146-147 reimbursement systems and, 25, 33-36, 72, 80 reimbursement systems in, 91 research needs, 81 societal context of, 78-79 Technology assessment alternative funding mechanisms, 184188 appropriateness methodology for, 138, 140-141 in biotechnology pharmaceutical companies, 164-165 in Blue Cross and Blue Shield Association, 96-98 categories of technology for, 103-104 collaboration in, 56, 57, 113, 114-115, 185-186 committees for, 51, 54, 63 consumers and, 176, 182 cost-benefit analysis, 141-143, 144-145 cost-effectiveness as criterion in, 8 cost of research in, 54, 57 current practice in, 51-53, 63 decision analysis in, 139-139 decision-making criteria, 4 definition, 49-50, 152, 154, 173-174 drug formulary, 50 n.1, 54 early-stage sponsorship, 189 economic considerations in, 55-56, 6263, 104-105 education/training for, 57 effectiveness in, 130 efficacy as measure in, 130, 153, 173 evolution of, 154-155 expenditures, 176-177 experimental trials, 79 government support for, 127, 175, 176, 183, 187-189, 198-199 health care reform and, 198 in hospitals, 62-63 information resources, 4, 53, 54-55, 56, 57-58, 72, 75-78, 79, 198-199 in Kaiser Permanente, 102-108 marketing considerations in, 180-181

Read the entire page →

From page 224...

... 224 INDEX medical device manufacturers and, 6, 155-159, 168-169, 175, 180-181 care in Medicare coverage decisions, 90, 92 models of management behavior in, 63 65 national body/procedures for, 113-115, 147-148, 185-186, 198 negative findings in, 181 obsolescence as evaluation criterion, 81 obstacles to, 56-57, 81, 143-147, 190 optimal process, 148-149 outcomes research in, 130-131, 153 patient perspective in, 141-142 by pharmaceutical companies, 159-164, 169, 175, 180-181 quality-adjusted life years, 142 quality of, 53-55 regulatory considerations, 55 responsibility for, 6 role of, 49, 50, 53, 128, 190-191 selection of technologies for, 177-179 short-term vs. long-term outcomes in, 66-68 societal perspectives in, 65-69, 105- system, 27 106, 107-108 sponsors of 174-176, 179-184, 181, 186-188, 190-191 stages of, 173-174 standards, 189-190 timing of, 66 trends, 56-58, 166 See also Outcomes research; Quality of Third-party payers in Medicare coverage decisionmaking, 91-92 technology assessment by, 51, 53, 54, 149, 156 Tissue plasminogen activator, 30 Transplant procedures, 14, 19, 21, 25-26, 30 in Medicare coverage, 92-93 Travelers' Insurance, 91-92 Treatment decisions cost-benefit analysis in, 145-146 coverage decisionmaking and, 4-5 influences in, 4 patient perspective in, 141-142 Uniform Clinical Data Set, 135 United Kingdom, 13 dialysis coverage in, 20 Unnecessary operations, 12 n.6 Utilization, in prospective payment Vaccines, 20-21, 22-23 Veterans Affairs, Department of, 176, 177 Victim v.

Read the entire page →

← Previous Chapter Skim

This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.

INDEX Pages 217-224

INDEX
Pages 217-224